Artia Global Partners LP Makes New $4.93 Million Investment in Sionna Therapeutics, Inc. $SION

Artia Global Partners LP bought a new position in Sionna Therapeutics, Inc. (NASDAQ:SION) during the 4th quarter, HoldingsChannel.com reports. The fund bought 119,741 shares of the company’s stock, valued at approximately $4,926,000. Sionna Therapeutics accounts for about 0.7% of Artia Global Partners LP’s portfolio, making the stock its 22nd biggest position.

Several other institutional investors and hedge funds have also modified their holdings of the business. Goldman Sachs Group Inc. acquired a new stake in shares of Sionna Therapeutics in the 1st quarter valued at $667,000. Woodline Partners LP bought a new stake in Sionna Therapeutics in the first quarter worth $837,000. Geode Capital Management LLC boosted its holdings in Sionna Therapeutics by 113.4% in the second quarter. Geode Capital Management LLC now owns 289,275 shares of the company’s stock worth $5,020,000 after purchasing an additional 153,712 shares in the last quarter. Rhumbline Advisers bought a new stake in Sionna Therapeutics in the second quarter worth $307,000. Finally, New York State Common Retirement Fund acquired a new stake in shares of Sionna Therapeutics in the second quarter worth about $118,000.

Insider Activity

In related news, Director Orbimed Advisors Llc sold 235,863 shares of the business’s stock in a transaction dated Wednesday, April 15th. The stock was sold at an average price of $44.64, for a total transaction of $10,528,924.32. Following the completion of the transaction, the director owned 3,247,025 shares of the company’s stock, valued at approximately $144,947,196. The trade was a 6.77% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Peter A. Thompson sold 235,863 shares of the business’s stock in a transaction dated Wednesday, April 15th. The stock was sold at an average price of $44.64, for a total value of $10,528,924.32. Following the transaction, the director directly owned 3,247,025 shares of the company’s stock, valued at $144,947,196. This represents a 6.77% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 1,717,962 shares of company stock valued at $77,571,889 in the last three months. 5.10% of the stock is owned by insiders.

Sionna Therapeutics Price Performance

Shares of NASDAQ:SION opened at $36.73 on Thursday. Sionna Therapeutics, Inc. has a fifty-two week low of $13.81 and a fifty-two week high of $48.44. The stock has a market capitalization of $1.66 billion, a P/E ratio of -19.03 and a beta of 1.30. The business has a 50-day moving average of $39.87 and a two-hundred day moving average of $39.50.

Sionna Therapeutics (NASDAQ:SION) last posted its quarterly earnings data on Tuesday, May 12th. The company reported ($0.60) earnings per share for the quarter, missing the consensus estimate of ($0.52) by ($0.08). As a group, research analysts expect that Sionna Therapeutics, Inc. will post -2.57 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

SION has been the subject of a number of analyst reports. BTIG Research reaffirmed a “buy” rating and issued a $58.00 price target on shares of Sionna Therapeutics in a research report on Wednesday, May 13th. Citizens Jmp reaffirmed a “market outperform” rating and issued a $63.00 price target on shares of Sionna Therapeutics in a research report on Tuesday, May 26th. Lifesci Capital raised Sionna Therapeutics to a “strong-buy” rating in a research report on Wednesday, February 25th. Guggenheim boosted their price target on Sionna Therapeutics from $45.00 to $50.00 and gave the stock a “buy” rating in a research report on Monday, March 2nd. Finally, Wedbush initiated coverage on Sionna Therapeutics in a research report on Tuesday, May 5th. They issued an “outperform” rating and a $53.00 price target for the company. Three research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $53.22.

About Sionna Therapeutics

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.